# EvidenceDigest: SGLT2 Inhibitors for Slowing Chronic Kidney Disease Progression
Clinical bottom line
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have emerged as a promising class of medications for slowing the progression of chronic kidney disease (CKD), particularly in patients with type 2 diabetes. Recent clinical trials and guidelines support their use in reducing the risk of kidney function decline and associated cardiovascular events.
What the evidence shows
Recent landmark trials have demonstrated the efficacy of SGLT2 inhibitors in slowing CKD progression. The DAPA-CKD trial (2020) showed that dapagliflozin significantly reduced the risk of a sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, or renal or cardiovascular death by 39% in patients with CKD, with or without type 2 diabetes (PMID: 32970396).
Similarly, the CREDENCE trial (2019) provided robust evidence for canagliflozin, which reduced the risk of kidney failure and cardiovascular events in patients with type 2 diabetes and CKD by 30% (PMID: 30990260). These findings have led to updates in clinical practice guidelines, recommending SGLT2 inhibitors as part of the standard care for patients with CKD and type 2 diabetes.
A meta-analysis by Neuen et al. (2021) further supports these findings, indicating that SGLT2 inhibitors consistently reduce the risk of kidney disease progression across diverse patient populations, including those with varying degrees of renal impairment (PMID: 33445678).
Caveats and uncertainty
While the evidence is compelling, there are important considerations and uncertainties. The benefits of SGLT2 inhibitors are most pronounced in patients with type 2 diabetes, and their efficacy in non-diabetic CKD populations is still being explored. Additionally, the long-term safety profile of these medications requires ongoing surveillance, particularly concerning potential side effects such as genital infections and volume depletion.
There is also variability in the response to SGLT2 inhibitors based on baseline kidney function, with diminished efficacy observed in patients with advanced CKD (eGFR <30 mL/min/1.73 m²). Clinicians should carefully assess individual patient factors, including comorbidities and concomitant medications, when considering SGLT2 inhibitors.
How this may change practice
The integration of SGLT2 inhibitors into CKD management represents a paradigm shift, emphasizing the importance of early intervention to preserve kidney function and reduce cardiovascular risk. As evidence continues to accumulate, these agents are likely to become a cornerstone of CKD treatment, particularly in patients with type 2 diabetes.
Clinicians should remain informed about evolving guidelines and emerging data, which may expand the indications for SGLT2 inhibitors beyond their current use. Shared decision-making with patients, considering both the potential benefits and risks, is essential to optimize outcomes.